Advanced

IGF-I in the clinics : Use in retinopathy of prematurity

Hellström, Ann; Ley, David LU ; Hansen-Pupp, Ingrid LU ; Hallberg, Boubou; Ramenghi, Luca A.; Löfqvist, Chatarina; Smith, Lois E H and Hård, Anna Lena (2016) In Growth Hormone and IGF Research 30-31. p.75-80
Abstract

Retinopathy of prematurity is a potentially blinding disease, which is associated with low neonatal IGF-I serum concentrations and poor growth. In severe cases impaired retinal vessel growth is followed by pathologic neovascularization, which may lead to retinal detachment. IGF-I may promote growth even in catabolic states. Treating preterm infants with recombinant human (rh) IGF-I to concentrations normally found during gestation has been suggested to have a preventative effect on ROP. A recent phase 2 study treating infants (gestational age between 23. weeks+0. days and 27. weeks +. 6. days) with rhIGF-I/IGF binding protein-3 until 30 postmenstrual weeks showed no effect on ROP but a 53% reduction in severe bronchopulmonary dysplasia... (More)

Retinopathy of prematurity is a potentially blinding disease, which is associated with low neonatal IGF-I serum concentrations and poor growth. In severe cases impaired retinal vessel growth is followed by pathologic neovascularization, which may lead to retinal detachment. IGF-I may promote growth even in catabolic states. Treating preterm infants with recombinant human (rh) IGF-I to concentrations normally found during gestation has been suggested to have a preventative effect on ROP. A recent phase 2 study treating infants (gestational age between 23. weeks+0. days and 27. weeks +. 6. days) with rhIGF-I/IGF binding protein-3 until 30 postmenstrual weeks showed no effect on ROP but a 53% reduction in severe bronchopulmonary dysplasia and 44% reduction in severe intraventricular hemorrhage. Oxygen is a major risk factor for ROP and during the phase 2 study oxygen saturation targets were increased to 90-95%, due to national guidelines, which might have affected ROP rate and severity making increased IGF-I a weaker preventative factor for ROP.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Fetus, IGF-I, Metabolism, Postnatal growth, Preterm infant, Preterm morbidity
in
Growth Hormone and IGF Research
volume
30-31
pages
75 - 80
publisher
Elsevier
external identifiers
  • scopus:84992058856
  • wos:000390724400013
ISSN
1096-6374
DOI
10.1016/j.ghir.2016.09.005
language
English
LU publication?
yes
id
478602e2-b0a4-41b9-99da-6151a879a93e
date added to LUP
2016-11-04 10:46:30
date last changed
2017-09-18 11:29:19
@article{478602e2-b0a4-41b9-99da-6151a879a93e,
  abstract     = {<p>Retinopathy of prematurity is a potentially blinding disease, which is associated with low neonatal IGF-I serum concentrations and poor growth. In severe cases impaired retinal vessel growth is followed by pathologic neovascularization, which may lead to retinal detachment. IGF-I may promote growth even in catabolic states. Treating preterm infants with recombinant human (rh) IGF-I to concentrations normally found during gestation has been suggested to have a preventative effect on ROP. A recent phase 2 study treating infants (gestational age between 23. weeks+0. days and 27. weeks +. 6. days) with rhIGF-I/IGF binding protein-3 until 30 postmenstrual weeks showed no effect on ROP but a 53% reduction in severe bronchopulmonary dysplasia and 44% reduction in severe intraventricular hemorrhage. Oxygen is a major risk factor for ROP and during the phase 2 study oxygen saturation targets were increased to 90-95%, due to national guidelines, which might have affected ROP rate and severity making increased IGF-I a weaker preventative factor for ROP.</p>},
  author       = {Hellström, Ann and Ley, David and Hansen-Pupp, Ingrid and Hallberg, Boubou and Ramenghi, Luca A. and Löfqvist, Chatarina and Smith, Lois E H and Hård, Anna Lena},
  issn         = {1096-6374},
  keyword      = {Fetus,IGF-I,Metabolism,Postnatal growth,Preterm infant,Preterm morbidity},
  language     = {eng},
  month        = {08},
  pages        = {75--80},
  publisher    = {Elsevier},
  series       = {Growth Hormone and IGF Research},
  title        = {IGF-I in the clinics : Use in retinopathy of prematurity},
  url          = {http://dx.doi.org/10.1016/j.ghir.2016.09.005},
  volume       = {30-31},
  year         = {2016},
}